Comparison between Env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 1, 2003, Pages 9-17

  Ratto Kim, Silvia ^a,f   Loomis Price, Lawrence D ^a   Aronson, Naomi ^c,d   Grimes, Janelle ^a   Hill, Cristin ^a   Williams, Chevelle ^a   El Habib, Raphaelle ^e   Birx, Deborah L ^b   Kim, Jerome H ^b,d  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e SANOFI PASTEUR   (France)

^f UNIVERSITY OF HAWAII   (United States)

Author keywords

ALVAC HIV(vCP205) in combination with rgp160MN LAI 2; HIV 1 infected adults; HIV 1 uninfected adults; T helper responses

Indexed keywords

ALVAC HIV(VCP205); CD4 ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RGP 160MN LAI 2; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0037231506     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200301010-00003     Document Type: Article

References (31)

1. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-204.
2. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68:8056-63.
3. Ostrowski MA, Justement SJ, Ehler L, et al. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses. J Immunol 2000;165:6133-41.
4. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
5. Birx DL, Redfield RR, Tencer K, et al. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990;76:2303-10.
6. Lane HC, Depper JM, Greene WC, et al. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985;313:79-84.
7. Miedema F, Petit AJ, Terpstra FG. et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988;82:1908-14.
8. Musey LK, Krieger JN, Hughes JP, et al. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 1999;180:278-84.
9. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417:95-8.
10. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-50.
11. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
12. Altfeld M, Rosenberg ES. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol 2000;12:375-80.
13. Heeney JL. The critical role of CD4(+) T-cell help in immunity to HIV. Vaccine 2002;20:1961-3.
14. The AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 2001;183:563-70.
15. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-52.
16. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-46.
17. Gorse GJ, Patel GB, Belshe RB. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers, AIDS Res Hum Retroviruses 2001;17:1175-89.
18. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002;29:254-61.
19. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-401.
20. Ferrari G, Neal W, Jones A, et al. CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. Immunol Lett 2001;79:37-45.
21. Chujoh Y, Matsuo K, Yoshizaki H, et al. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B′ strains by recombinant Mycobacterium bovis BCG-based candidate vaccine. Vaccine 2001;20:797-804.
22. Verrier F, Burda S, Belshe R, et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dual tropic clade B and C primary isolates. J Virol 2000;74:10025-33.
23. Loomis-Price L. Linear epitope mapping by the Pepscan method. In Michael N, Kim J, eds. Methods in molecular medicine. Totowa: Humana Press. 1998:293-307.
24. Carter JM. Epitope mapping of a protein using the Geysen (PEPSCAN) procedure. In Dunn BM, Pennington MW, eds. Methods in molecular biology. Totowa: Humana Press, 1994:207-23.
25. Valerio RM, Benstead M, Bray AM, et al. Synthesis of peptide analogues using the multipin peptide synthesis method. Anal Biochem 1991;197:168-77.
26. Bugawan TL, Apple R, Erlich HA. A method for typing polymorphism at the HLA-A locus using PCR amplification and immobilized oligonucleotide probes. Tissue Antigens 1994;44:137-47.
27. Ratto S, Sitz KV, Scherer AM, et al. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients. J Infect Dis 1995;171:1420-30.
28. HIV databases [database online]. Los Alamos, AZ: National Laboratories, 2002. Updated March 5, 2002.
29. Ratto S, Sitz KV, Scherer AM, et al. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:128-36.
30. Sitz KV, Loomis-Price LD, Ratto-Kim S, et al. Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons. J Infect Dis 1997;176:1085-9.
31. Fang ZY, Kuli-Zade I, Spearman P. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate. J Infect Dis 1999;180:1122-32.